Ro Isaac
Known title: Chief Financial OfficerCIK: 0001873463
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
GeneDx Shares New Genomic Newborn Screening Data. GeneDx presented new evidence for its genomic newborn screening program at the ICoNS 2026 conference. This update highlights the company's ongoing development in clinical genomics. The stock is currently trading near its 52-week low, with an average analyst target of $93.50.
Transaction History
| SEER | ▲ Buy | Grant | 12,375 | $0 | 7/28/2026 | View on chart |
| SEER | ▲ Buy | Grant | 41,000 | $0 | 9/2/2025 | View on chart |
| WGS | ▼ Sell | Open Market | 20,245 | $40K | 8/9/2022 | View on chart |
| WGS | ▲ Buy | Option Exercise | 62,500 | — | 8/8/2022 | View on chart |
| WGS | ▼ Sell | Open Market | 2,296 | $3K | 7/5/2022 | View on chart |
| WGS | ▲ Buy | Option Exercise | 7,396 | — | 7/1/2022 | View on chart |
| WGS | ▼ Sell | Open Market | 19,515 | $48K | 5/10/2022 | View on chart |
| WGS | ▲ Buy | Option Exercise | 62,500 | — | 5/8/2022 | View on chart |
| WGS | ▼ Sell | Open Market | 1,284 | $4K | 4/6/2022 | View on chart |
| WGS | ▲ Buy | Grant | 3,896 | $0 | 4/4/2022 | View on chart |
| WGS | ▼ Sell | Open Market | 21,735 | $78K | 2/10/2022 | View on chart |
| WGS | ▲ Buy | Option Exercise | 62,500 | — | 2/8/2022 | View on chart |
| WGS | ▼ Sell | Tax Withholding | 215 | $1K | 12/1/2021 | View on chart |
| WGS | ▲ Buy | Grant | 618 | $4K | 12/1/2021 | View on chart |
| WGS | ▼ Sell | Open Market | 12,115 | $80K | 11/29/2021 | View on chart |
| WGS | ▲ Buy | Option Exercise | 62,500 | — | 11/8/2021 | View on chart |
| WGS | ▼ Sell | Open Market | 19,516 | $166K | 11/8/2021 | View on chart |
| WGS | ▲ Buy | Option Exercise | 125,000 | — | 10/25/2021 | View on chart |
| WGS | ▼ Sell | Open Market | 40,848 | $308K | 10/25/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Seer to Present Proteomics Data at HUPO 2026; CFO Transition Announced
Seer Inc. will share early results from its PRECISE-SG100K proteomics study with Nanyang Technological University at the HUPO 2026 conference. The company also announced a transition in its Chief Financial Officer role. These developments provide updates on the firm's scientific progress and leadership structure.
Seer to Present Proteomics Data at HUPO 2026; CFO Transition Announced. Seer Inc. will share early results from its PRECISE-SG100K proteomics study with Nanyang Technological University at the HUPO 2026 conference. The company also announced a transition in its Chief Financial Officer role. These developments provide updates on the firm's scientific progress and leadership structure.